These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19200218)

  • 21. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival.
    Wheless SA; Gulley ML; Raab-Traub N; McNeillie P; Neuringer IP; Ford HJ; Aris RM
    Am J Respir Crit Care Med; 2008 Nov; 178(10):1060-5. PubMed ID: 18755927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease.
    Carpentier L; Tapiero B; Alvarez F; Viau C; Alfieri C
    J Infect Dis; 2003 Dec; 188(12):1853-64. PubMed ID: 14673764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In situ hybridization for Epstein-Barr virus NotI repeats in posttransplant lymphoproliferative disorder.
    Montone KT; Friedman H; Hodinka RL; Hicks DG; Kant JA; Tomaszewski JE
    Mod Pathol; 1992 May; 5(3):292-302. PubMed ID: 1323104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
    Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
    Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
    J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients.
    Toyoda M; Moudgil A; Warady BA; Puliyanda DP; Jordan SC
    Pediatr Transplant; 2008 Nov; 12(7):778-84. PubMed ID: 18331541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD.
    Davis JE; Sherritt MA; Bharadwaj M; Morrison LE; Elliott SL; Kear LM; Maddicks-Law J; Kotsimbos T; Gill D; Malouf M; Falk MC; Khanna R; Moss DJ
    Int Immunol; 2004 Jul; 16(7):983-9. PubMed ID: 15159377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection.
    Ahya VN; Douglas LP; Andreadis C; Arnoldi S; Svoboda J; Kotloff RM; Hadjiliadis D; Sager JS; Woo YJ; Pochettino A; Schuster SJ; Stadtmauer EA; Tsai DE
    J Heart Lung Transplant; 2007 Aug; 26(8):839-44. PubMed ID: 17692789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR.
    Michelson P; Watkins B; Webber SA; Wadowsky R; Michaels MG
    Pediatr Transplant; 2008 Jun; 12(4):464-8. PubMed ID: 18466434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
    Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF
    Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
    Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
    Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
    Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J
    Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
    Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
    Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.